Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06698263
PHASE4

13-cis Retinoic Acid (Isotretinoin) and Sperm Production

Sponsor: University Hospital, Strasbourg, France

View on ClinicalTrials.gov

Summary

This study aims to evaluate the effectiveness of weekly administration of isotretinoin (40 mg) in increasing sperm production in men with oligozoospermia, a condition characterized by a low sperm count. Participants will be randomized into two groups: one receiving isotretinoin and the other a placebo. The primary outcome will be the change in sperm production over 20 weeks of treatment.

Key Details

Gender

MALE

Age Range

21 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

100

Start Date

2025-03-01

Completion Date

2027-12-01

Last Updated

2024-11-25

Healthy Volunteers

No

Interventions

DRUG

Isotretinoin

ARESPERM is a multicenter, randomized, double-blind, placebo-controlled study that assesses whether a weekly dose of isotretinoin can stimulate spermatogenesis in men with oligozoospermia. The study hypothesizes that isotretinoin can trigger the differentiation of spermatogonial cells, leading to improved sperm production.

DRUG

Control group (placebo)

placebo administration

Locations (1)

CECOS Alsace Strasbourg

Schiltigheim, France